HGF mimetic raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-09. Anything still debated is marked as such rather than presented as settled.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Boris Savinkov, leader of the organization Phlegont Klepikov, secretary and treasurer Colonel Alexander Perkhurov, chief of staff Colonel Karl Gopper, head of military personnel Colonel Stradetsky, liaison with the Volunteer Army Colonel Friedrich Briedis, responsible for intelligence, counterintelligence, and anti-Bolshevik propaganda among the Latvian Riflemen Doctor Aksanin (Nikolai Sergeyevich Grigoryev), head of the provincial and propaganda section Captain Alexander Vilenkin, head of the cavalry center Captain Schroeder, head of the artillery center Alexander Dikgof-Derenthal, who helped maintain contact with foreign missions Lyubov Dikgof, secretary to Savinkov
== Education == Primary schools in the town are: Buttsbury, Brightside, Sunnymede and South Green. There are two secondary comprehensives: Billericay School and Mayflower High School. St John's School in an independent school for children up to the age of 18.
Vitamin K: CID 5280483 from PubChem Vitamin K1 (phylloquinone, phytomenadione): CID 5284607 from PubChem Vitamin K2 (menaquinone 6): CID 5283547 from PubChem Vitamin K3 (menadione): CID 4055 from PubChem
In 2001, the Raleigh Memorial Auditorium complex was expanded with the addition of the Progress Energy Center for the Performing Arts, Meymandi Concert Hall, Fletcher Opera Theater, Kennedy Theatre, Betty Ray McCain Gallery and Lichtin Plaza. Fayetteville Street reopened to vehicular traffic in 2006. A variety of downtown building projects began around this time including the 34-story RBC Bank Tower, multiple condominium projects and several new restaurants. Additional skyscrapers are in the proposal/planning phase. The Carolina Hurricanes won the Stanley Cup the same year, which was North Carolina's first professional sports championship. With the opening of parts of I-540 from 2005 to 2007, a new 70 mi (110 km) loop around Wake County, traffic congestion eased somewhat in the North Raleigh area. Completion of the entire loop is expected to take another 15 years. In 2008, the city's Fayetteville Street Historic District joined the National Register of Historic Places. In September 2010, Raleigh hosted the inaugural Hopscotch Music Festival. Raleigh hosted the 2011 National Hockey League All-Star Game. In April 2011, a devastating EF-3 tornado hit Raleigh, and many other tornadoes touched down in the state (ultimately the largest, but not the strongest outbreak to ever hit the state), killing 24 people. The tornado tracked northeast through parts of downtown, East Central Raleigh and Northeast Raleigh and produced $115 million in damages in Wake County. There were 4 fatalities in the city.
Short-chain scorpion toxins constitute the largest group of potassium (K+) channel-blocking peptides. An important physiological role of the KCNA3 channel, also known as KV1.3, is to help maintain large electrical gradients for the sustained transport of ions such as Ca2+ that controls T lymphocyte (T cell) proliferation. Thus KV1.3 blockers could be potential immunosuppressants for the treatment of autoimmune disorders (such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis). The venom of Uroplectes lineatus is clinically important in dermatology. Several scorpion venom toxins have been investigated for medical use. Chlorotoxin from the deathstalker scorpion (Leiurus quinquestriatus); the toxin blocks small-conductance chloride channels; Maurotoxin from the venom of the Tunisian Scorpio maurus blocks potassium channels. Some antimicrobial peptides in the venom of Mesobuthus eupeus; meucin-13 and meucin-18 have extensive cytolytic effects on bacteria, fungi, and yeasts, while meucin-24 and meucin-25 selectively kill Plasmodium falciparum and inhibit the development of Plasmodium berghei, both malaria parasites, but do not harm mammalian cells.
Sources: en.wikipedia.org
Clinical endpoints or clinical outcomes are outcome measures referring to occurrence of disease, symptom, sign or laboratory abnormality constituting a target outcome in clinical research trials. The term may also refer to any disease or sign that strongly motivates withdrawal of an individual or entity from the trial, then often termed a humane (clinical) endpoint. The primary endpoint of a clinical trial is the endpoint for which the trial is powered. Secondary endpoints are additional endpoints, preferably also pre-specified, for which the trial may not be powered. Surrogate endpoints are trial endpoints that have outcomes that substitute for a clinical endpoint, often because studying the clinical endpoint is difficult, for example using an increase in blood pressure as a surrogate for death by cardiovascular disease, where strong evidence of a causal link exists.
Aldehyde tags were first inserted into the modified sulfatase motif peptide for proteins of interest in 2007. Since then, similar usage of aldehydes and ketones as chemical reporters in bioorthogonal applications has been demonstrated in self-assembly of cell-lysing drugs, the targeting of proteins, as well as glycans and the preparation of heterobifunctional fusion proteins.
Recently, the metal core-dielectric shell nanoparticle has demonstrated a zero backward scattering with enhanced forward scattering on a silicon substrate when surface plasmon is located in front of a solar cell.
== Versus point of zero charge == The terms isoelectric point (IEP) and point of zero charge (PZC) are often used interchangeably, although under certain circumstances, it may be productive to make the distinction. In systems in which H+/OH− are the interface potential-determining ions, the point of zero charge is given in terms of pH. The pH at which the surface exhibits a neutral net electrical charge is the point of zero charge at the surface. Electrokinetic phenomena generally measure zeta potential, and a zero zeta potential is interpreted as the point of zero net charge at the shear plane. This is termed the isoelectric point. Thus, the isoelectric point is the value of pH at which the colloidal particle remains stationary in an electrical field. The isoelectric point is expected to be somewhat different from the point of zero charge at the particle surface, but this difference is often ignored in practice for so-called pristine surfaces, i.e., surfaces with no specifically adsorbed positive or negative charges. In this context, specific adsorption is understood as adsorption occurring in a Stern layer or chemisorption. Thus, point of zero charge at the surface is taken as equal to isoelectric point in the absence of specific adsorption on that surface. According to Jolivet, in the absence of positive or negative charges, the surface is best described by the point of zero charge. If positive and negative charges are both present in equal amounts, then this is the isoelectric point.
An injection port is a medical device used for the administration of insulin or other physician-approved medicine into the subcutaneous tissue (the tissue layer just below the skin). The device is similar to infusion sets used by insulin pumps, except it is configured to receive a syringe instead of a tubing system. An injection port is usually a disposable device applied by the patient and worn for period of 3–5 days. When giving shots via an injection port, the needle stays above the surface of the skin Medication is delivered via a short soft cannula. An injection port can be used in conjunction with multiple daily injections of insulin by people with diabetes. It can also be used for the subcutaneous administration of any other physician prescribed medication.
Sources: en.wikipedia.org
== Prevalence == In the United States, approximately 40,000 people were lobotomized, and in England, 17,000 lobotomies were performed. According to one estimate, in the three Nordic countries of Denmark, Norway, and Sweden, a combined figure of approximately 9,300 lobotomies was performed. Scandinavian hospitals lobotomized 2.5 times as many people per capita as hospitals in the US. According to another estimate, Sweden lobotomized at least 4,500 people between 1944 and 1966, mainly women. This figure includes young children. And in Norway, there were 2,005 known lobotomies. In Denmark, there were 4,500 known lobotomies. The Soviet Union banned the practice in 1950 on moral grounds. In Germany, it was performed only a few times. By the late 1970s, the practice of lobotomy had generally ceased, although it continued as late as the 1980s in France. As of 2019, legality of the procedure in the United States varies according to state law, with some states restricting it heavily, while others effectively leave its regulation to laws of general applicability.
The overall life expectancy in Colombia at birth is 79.3 years (76.7 years for males and 81.9 years for females). Healthcare reforms have led to massive improvements in the healthcare systems of the country, with health standards in Colombia improving very much since the 1980s. The new system has widened population coverage by the social and health security system from 21% (pre-1993) to 96% in 2012. In 2017, the government declared a cancer research and treatment center as a Project of National Strategic Interest. A 2016 study conducted by América Economía magazine ranked 21 Colombian health care institutions among the top 44 in Latin America, amounting to 48 percent of the total. In 2022, 26 Colombian hospitals were among the 61 best in Latin America (42% total). Also in 2023, two Colombian hospitals were among the top 75 of the world.
== Characters == The story, as a whole, does not feature a single character who constantly plays the leading role. Each major narrative arc (e.g., Dance of..., The Archer of...) features its corresponding Agent and Guard or Archer and Custodian.
The former presence of 244Pu in the early Solar System has been confirmed, since it manifests itself today as an excess of its daughters, either 232Th (from the alpha decay pathway) or xenon isotopes (from its spontaneous fission). The latter are generally more useful, because the chemistries of thorium and plutonium are rather similar (both are predominantly tetravalent) and hence an excess of thorium would not be strong evidence that some of it was formed as a plutonium daughter. 244Pu has the longest half-life of all transuranic nuclides and is produced only in the r-process in supernovae and colliding neutron stars; when nuclei are ejected from these events at high speed to reach Earth, 244Pu alone among transuranic nuclides has a long enough half-life to survive the journey, and hence tiny traces of live interstellar 244Pu have been found in the deep sea floor. Because 240Pu also occurs in the decay chain of 244Pu, it must thus also be present in secular equilibrium, albeit in even tinier quantities. Astrophysical detection of plutonium is extremely limited, but is found in the spectrum of the extremely chemically peculiar Przybylski's Star. Minute traces of plutonium are usually found in the human body due to the 550 atmospheric and underwater nuclear tests that have been carried out, and to a small number of major nuclear accidents. Most atmospheric and underwater nuclear testing was stopped by the Limited Test Ban Treaty in 1963, which of the nuclear powers was signed and ratified by the United States, United Kingdom and Soviet Union.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.